Diabetes drug appears to work for weight management, reversing prediabetes

June 23, 2014, The Endocrine Society

Nondiabetic obese and overweight people lose more weight, are more likely to reverse prediabetes and are slower to develop type 2 diabetes when they take the diabetes drug liraglutide in addition to dieting and exercising, a new study finds. The results of the multicenter study were presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

Study subjects who received a 3-milligram (3-mg) dose of liraglutide lost an average of 8 percent of their body weight (18.7 pounds), compared with just 2.6 percent (6.2 pounds) for subjects receiving a placebo, or "dummy" drug, the investigators reported.

"An 8 percent weight loss is as good as with any weight loss drug on the market," said F. Xavier Pi-Sunyer, MD, MPH, the study's principal investigator and an endocrinologist at St. Luke's-Roosevelt Hospital Center in New York City.

Liraglutide 3 mg is an investigational product and is not approved by the FDA. Liraglutide (1.2 and 1.8 mg) is exclusively marketed globally under the brand name Victoza® for the treatment of adults with to improve glycemic control. The drug is not approved for weight management, according to its manufacturer, Denmark-based Novo Nordisk, which sponsored this study, called the SCALE™ (Satiety and Clinical Adiposity-Liraglutide Evidence in Nondiabetic and Diabetic Subjects) Obesity and Prediabetes trial.

The study included 3,731 obese adults and overweight adults who had at least one other risk factor for heart disease, such as , high blood pressure or high cholesterol. As part of their , all subjects exercised and ate 500 fewer calories than usual. In addition, they were randomly assigned, in a 2-to-1 ratio, to a once-daily injection with either 3 mg of liraglutide or placebo for 56 weeks. Neither the subjects nor the investigators knew who received the active drug. Subjects who received liraglutide started at a dose of 0.6 mg, which gradually was increased to 3 mg, to minimize side effects, such as nausea.

The study had two arms. In the first arm, which included 1,446 adults who did not have prediabetes, 959 received liraglutide and 487 got the placebo. For the second arm, among 2,285 individuals with prediabetes, liraglutide went to 1,528 of them and placebo to 757.

Among subjects who had prediabetes at the beginning of the study (arm 2), blood sugar levels reverted to normal in nearly 70 percent of those receiving liraglutide versus 32 percent of people in the placebo group, according to the abstract. Liraglutide also lowered the chance of prediabetes developing in adults who started the study with normal , with 7 percent becoming prediabetic compared with nearly 20 percent of those receiving placebo.

Study data also showed that type 2 diabetes developed in three times as many people receiving as those who took liraglutide (14 subjects versus four, respectively).

"The delay in progression to type 2 diabetes with liraglutide use is likely due to increased weight loss," Pi-Sunyer said.

The SCALE Obesity and Prediabetes trial is continuing for two more years for the prediabetic in arm 2. Twelve-week results show that liraglutide treatment continues to sustain the , Pi-Sunyer reported.

Explore further: Liraglutide augments weight loss in pre-type 2 diabetes

Related Stories

Liraglutide augments weight loss in pre-type 2 diabetes

August 15, 2013
(HealthDay)—For patients at high risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), liraglutide in additional to calorie restriction is associated with more weight loss and improvements in insulin ...

Diabetes drug may spur weight loss in obese nondiabetics

May 30, 2014
(HealthDay)—A higher dose of the diabetes drug liraglutide (Victoza) may help obese people without the disease lose weight, a new study suggests.

Liraglutide with insulin improves poorly controlled Type 1 diabetes

June 25, 2012
Obese adults with poorly controlled Type 1 diabetes can better control their blood sugar by adding liraglutide, a Type 2 diabetes drug, to their insulin therapy, a new study finds. The results, which will be presented at ...

Head-to-head trial of two diabetes drugs yields mixed results

November 6, 2012
A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.

Drug combination promotes weight loss in polycystic ovary syndrome

June 17, 2013
Women with polycystic ovary syndrome, or PCOS, lost significantly more weight when they took two drugs that are traditionally used to treat diabetes, rather than either drug alone, a study from Slovenia demonstrates. The ...

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Thirty-year study shows women who breastfeed for six months or more reduce their diabetes risk

January 16, 2018
In a long-term national study, breastfeeding for six months or longer cuts the risk of developing type 2 diabetes nearly in half for women throughout their childbearing years, according to new Kaiser Permanente research published ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.